Korean J Med.
1999 Mar;56(3):292-298.
Clinical Value of Plasma Vascular Endothelial Growth Factor in Patients with Stomach Cancer
- Affiliations
-
- 1Department of Internal Medicine, College of Medicine, Soonchunhyang University.
- 2Department of Surgery, College of Medicine, Soonchunhyang University.
- 3Department of Pathology, College of Medicine, Soonchunhyang University.
Abstract
OBJECTIVE
Angiogenesis is an essential step in growth and metastasis of solid tumors.
Vascular endothelial growth factor(VEGF) is one of the most important mediators of angiogenesis.
VEGF selectively stimulates endothelial cell proliferation and induces angiogenesis. Also VEGF
was expressed by several human solid tumors and serum VEGF levels have previously been shown to
be raised in patients with breast cancer, gastrointestinal cancer, renal cancer and melanoma.
To evaluate the clinical value of plasma VEGF of patients with stomach cancer we studied
correlations between plasma VEGF, tumor stage, tumor resection and microvessel invasion by tumor.
METHODS
VEGF level was measured by ELISA methods in plasmas from 88 patients and after surgical
tumor resection from 48 patients with gastric carcinoma. Microvessel staining was done by
immunohistochemical staining using anti-CD34 monoclonal antibody on paraffin embedded tissues.
RESULTS
The plasma VEGF levels were significantly higher in the stomach cancer patients than
in normal controls(p<0.0001). In stomach cancer patients, plasma VEGF level was significantly
increased according to stage progression(p<0.05). Moreover early cancer, T1, showed a
significantly elevation of plasma VEGF level than that of controls. The level of plasma
VEGF fell after surgical resection(n=48) of stomach cancer(p<0.05). Also the plasma VEGF
levels were significantly higher in microvessel invasion by tumor(n=25) than in those without
invasion(n=19)(p<0.05).
CONCLUSION
In conclusion, plasma VEGF may be useful for predicting
disease status and prognosis of patients with stomach cancer.